Testimony of Pat Mooney
Executive Director of ETC Group
Before the Standing Committee on Energy, the Environment and Natural Resources-regarding Bill C-33 (the “Biofuels Bill”)
Senate of Canada
Wednesday, June 25, 2008
Thank you. I will begin by confessing that I am not an expert on biofuels. I feel as though my life has been hijacked by biofuels over [...]
The BP-Berkeley deal, the new joint Bio Energy institute, and also the recent job hop by John Menlo of BP fuels to Amyris Biotech - are all extra strings tying the interests of the Syn Bio community as a wholeever closer to the interests of big business. It should be noted that in each of thse cases CEO Keasling plays a central role. The same man who claims to be developing Synthetic Biology to serve the worlds poor (via synthetic artemisinin) seems to be rather busy these days serving the fabulously rich.
Is Craig Venter, the so called “bad boy of biology”, about to announce the world’s first synthetic lifeform? (or ‘Syn’ for short)… we don’t know. According to New Scientist “rumours are circulating that his institute will soon unveil the first synthetic bacterium”. What we do know is that he has applied for a patent with broad claims that include a synthetic organism itself…
Further reflections on EPO’s May 3 decision to revoke Monsanto’s species-wide soybean patent
ETC Group has been receiving lots of emails and phone calls in the past few days about the defeat of Monsanto’s soybean patent one week ago. While most have been congratulatory a few have asked whether this wasn’t in fact a hollow victory [...]
In the midst of our new fight over geoengineering near the Galapagos, we’ve got good news over a very old fight with Monsanto… Hope Shand just phoned from Munich to say that the European Patent Office has agreed with ETC’s arguments and overturned Monsanto’s soybean “species” patent. There is no further appeal!!
In a couple of days Hope Shand from ETC Group will be in court in the European patent Office to challenge Monsanto’s Patent on Soy beans - a patent that we have been contesting for 13 years and that originally Monsanto themselves opposed!! You can read more about that here. In the meantime, ETC [...]
On October 10, ETC Group attended the US Food and Drug Administration’s first public meeting on nanotechnology. About 40 people had signed up to make presentations, and we were each given eight minutes to say our piece to the FDA’s newly-formed Nanotechnology Task Force. (You can read the text of ETC Group’s presentation here.)
It [...]
Nano-Drug’s Dirty Little Secret
ETC Group’s September 2006 report on nanomedicine, Nanotech Rx, requires some updating. After all, it’s nearly 30 days old. Our report mentions the nano-drug Abraxane, and it acknowledges that approval of the cancer drug was a watershed event for the nanotech industry. But important details are emerging. On October 1 the [...]
The Economist this week has a Special Report on Synthetic Biology , the new field of building artificial life forms from scratch. As is to be expected from the Economist, this is a fairly upbeat assesment of the technology that fails to mention the growing opposition to Synthetic Biology, signalled a few months ago when almost forty civil society groups, trade unions and scientific associations signed an open letter calling for caution.
Here at ETC we have been busy writing our own special report on Synthetic Biology (which we are calling ‘Extreme Genetic Engineering’ -
Not content with heading for the stars, the corporate sponsored X-Foundation that awards the X-prize has now set a bounty for commericalising the neXt frontier - the human genome. According to this article in the Wall Street Journal the X-foundation will award a new X-prize of between $5-$20 million to the first inventor of a gene sequencer that can decode the DNA of 100 people in a matter of weeks. behind it is craig venter, the genomics mogul.
(et cet er a) and other things; such as human rights, biodiversity, biopiracy, converging technologies, global governance and corporate concentration. An experimental growing plot for news, views and new ideas.
